Astellas and Medivation Receive Priority Review From FDA for XTANDI(R) (Enzalutamide) Capsules in Chemotherapy-Naive Advanced Prostate Cancer

[Marketwired] – Medivation, Inc. and Astellas Pharma Inc. today announced that the U.S. Food and Drug Administration has accepted for filing the supplemental New Drug Application to extend the indication for XTANDI® capsules … more

View todays social media effects on MDVN

View the latest stocks trending across Twitter. Click to view dashboard

See who Medivation is hiring next, click here to view